Spero presents at Chardan, and Spero Therapeutics stock costs EUR 0.99

Published on 10/20/2026 at 14:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Spero schedules a Chardan chat for October 20, 2026. SPRO stock costs EUR 0.99 on October 20, 2026, with USD 65.5 million market value on October 19, 2026.

Conference and quarterly context

Spero Therapeutics scheduled a Chardan fireside chat for October 20, 2026.
Spero reported earnings per share of USD -0.16 for the second quarter of 2026 against USD -0.17 consensus.
Spero Therapeutics stock trades at EUR 0.99 at 2:29 p.m. CEST at Lang & Schwarz on October 20, 2026.

SPRO, US84833T1034, Illustration mit AI erstellt.

Spero Therapeutics (US84833T1034) was trading at EUR 0.99 at Lang & Schwarz on October 20, 2026, at 2:29 p.m. CEST. The clinical-stage biotechnology company had scheduled a presentation at the Chardan 10th Annual Healthcare Conference for the same date, according to GlobeNewswire.

SP001 gives the conference its focus

Chief Executive Officer Esther Rajavelu was scheduled to take part in a fireside chat at 9:15 a.m. ET in New York. GlobeNewswire said the discussion would cover Spero's lead program, SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease. The release also said company executives would hold one-on-one meetings.

What does the quarterly loss show?

The latest reported quarter provides the clearest operating reference. Spero reported earnings per share of USD -0.16 for the second quarter of 2026, compared with consensus of USD -0.17, according to MarketBeat. The finance statements show revenue of USD 0.0 million and a net loss of USD 9.6 million for that quarter, while operating cash flow was negative USD 5.4 million.

Three dated steps for SPRO

On August 12, 2026, Spero released its second-quarter operating results and reported the USD -0.16 earnings-per-share figure. On October 1, 2026, the company approved 233,000 restricted stock units and 323,000 stock options for new employees, as reported by BioSpace. On October 15, 2026, Spero announced the October 20 conference appearance.

Next date is October 20

The scheduled company event was the October 20, 2026, Chardan fireside chat at 9:15 a.m. ET. Its timing puts management communication ahead of the next reported operating update.

Market value remains small

MarketBeat listed Spero's market capitalization at USD 65.5 million on October 19, 2026, with a 52-week range of USD 1.08 to USD 3.08. The company profile describes Spero as a biotechnology business with 25 employees and a pipeline centered on immunology and inflammation medicines.

Spero Therapeutics was trading at EUR 0.99 at Lang & Schwarz on October 20, 2026, at 2:29 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Spero Therapeutics stock.